Serum Untargeted UHPLC-HRMS-Based Lipidomics to Discover the Potential Biomarker of Colorectal Advanced Adenoma

Zhu, Yifan; Wang, Lisheng; Nong, Yanying; Liang, Yunxiao; Huang, Zongsheng; Zhu, Pingchuan; Zhang, Qisong

doi:10.2147/cmar.s336322

Cited by 11 publications

(15 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, as the severe stage of CA, colorectal advanced adenoma (CAA) was also considered the effective and ideal target for early prevention of CRC. In the previous investigation, we found that TAGs were the major dysregulated lipid species of CAA (12). In this study, we also found that TAGs were the main dysregulated lipid species in CA progression to CRC (Table 2, Figs.…”

Section: Discussionsupporting

confidence: 74%

“…For serum sample preparation, the detail method was referred to our previous study (12). 500 μL precooling dichloromethane-methanol (3:1, v/v) solution was added to 50 μL serum.…”

Section: Sample Preparationmentioning

confidence: 99%

“…The data processing procedures of serum lipidomics were based on our previous study (12). For univariate statistical analysis, raw data les were imported into the Thermo Scienti c Compound Discoverer TM 3.1 software for data analysis.…”

Section: Data Processing and Statistical Analysesmentioning

confidence: 99%

“…In recent years, mass spectrometry-based high throughput analytical technology has been widely used to identify new biomarkers of disease from numerous biological molecules (11,12). Following the genomics, transcriptomics, and proteomics, metabolomics as one of the typical representatives of high throughput mass spectrometry technique has attracted great attention for its application in screening, detection, and diagnosis of tumors (13).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Serum lipidomics reveals novel biomarkers by UHPLC-HRMS to assist the discrimination between colorectal adenoma and cancer

Chen

Zhang

Zhou

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Purpose The mechanisms of colorectal adenoma (CA) transforming colorectal cancer (CRC) remain unclear, and there are still lacking biomarkers to distinguish CA from CRC. Hence, this study aimed to explore underlying the mechanisms of CA canceration and novel biomarkers to differentiate CA from CRC. Methods An ultrahigh performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS) method was employed to measure global lipid profiles of 100 serum samples from CA and CRC patients. Univariate and multivariate statistical analysis were applied to select the differential lipids between two groups. Combining constituent ratio analysis and performance evaluation analysis by the receiver operating characteristic (ROC) curve explored the mechanisms of CA canceration and lipid markers to discriminate CA and CRC. Results Serum lipid profiles presented obvious differences between CA and CRC. Totally 85 differential lipids (P < 0.05 and fold change > 1.5) were discovered and mainly involved in fatty acid (FA), phosphatidylcholine (PC), and triacylglycerol (TAG) metabolism with ratio > 63%. 7 lipids served as the putative biomarkers with the area under the curve (AUC) > 0.800. Among them, a lipid panel containing four lipids was selected as the potential biomarkers with excellent performance (AUC = 0.971) and the highest selected frequency to distinguish CA from CRC based on SVM classification model. Conclusion The lipid panel could act as the potential biomarkers aiding the early diagnosis of CRC. Metabolic dysregulation of FAs, PCs, and TAGs should be involved in CA canceration, which provides new clues to understand its underlying mechanisms.

show abstract

Section: Discussionsupporting

confidence: 74%

“…For serum sample preparation, the detail method was referred to our previous study (12). 500 μL precooling dichloromethane-methanol (3:1, v/v) solution was added to 50 μL serum.…”

Section: Sample Preparationmentioning

confidence: 99%

Section: Data Processing and Statistical Analysesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum lipidomics reveals novel biomarkers by UHPLC-HRMS to assist the discrimination between colorectal adenoma and cancer

Chen

Zhang

Zhou

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, as the severity of CA progressed, it may transform into a colorectal advanced adenoma (CAA) and, as such, would also be considered an ideal target for early prevention of CRC. In the previous investigation, we found that TAGs were the major dysregulated lipid species of CAA (12).…”

Section: Discussionmentioning

confidence: 87%

UHPLC-HRMS–based serum lipisdomics reveals novel biomarkers to assist in the discrimination between colorectal adenoma and cancer

et al. 2022

Self Cite

View full text Add to dashboard Cite

The development of a colorectal adenoma (CA) into carcinoma (CRC) is a long and stealthy process. There remains a lack of reliable biomarkers to distinguish CA from CRC. To effectively explore underlying molecular mechanisms and identify novel lipid biomarkers promising for early diagnosis of CRC, an ultrahigh-performance liquid chromatography tandem high-resolution mass spectrometry (UHPLC-HRMS) method was employed to comprehensively measure lipid species in human serum samples of patients with CA and CRC. Results showed significant differences in serum lipid profiles between CA and CRC groups, and 85 differential lipid species (P < 0.05 and fold change > 1.50 or < 0.67) were discovered. These significantly altered lipid species were mainly involved in fatty acid (FA), phosphatidylcholine (PC), and triacylglycerol (TAG) metabolism with the constituent ratio > 63.50%. After performance evaluation by the receiver operating characteristic (ROC) curve analysis, seven lipid species were ultimately proposed as potential biomarkers with the area under the curve (AUC) > 0.800. Of particular value, a lipid panel containing docosanamide, SM d36:0, PC 36:1e, and triheptanoin was selected as a composite candidate biomarker with excellent performance (AUC = 0.971), and the highest selected frequency to distinguish patients with CA from patients with CRC based on the support vector machine (SVM) classification model. To our knowledge, this study was the first to undertake a lipidomics profile using serum intended to identify screening lipid biomarkers to discriminate between CA and CRC. The lipid panel could potentially serve as a composite biomarker aiding the early diagnosis of CRC. Metabolic dysregulation of FAs, PCs, and TAGs seems likely involved in malignant transformation of CA, which hopefully will provide new clues to understand its underlying mechanism.

show abstract

Recent Progress in Mass Spectrometry-based Metabolomics for Colorectal Cancer

Xiao

Chi

Wang

2022

Chem. Res. Chin. Univ.

View full text Add to dashboard Cite

Serum Untargeted UHPLC-HRMS-Based Lipidomics to Discover the Potential Biomarker of Colorectal Advanced Adenoma

Cited by 11 publications

References 46 publications

Serum lipidomics reveals novel biomarkers by UHPLC-HRMS to assist the discrimination between colorectal adenoma and cancer

Serum lipidomics reveals novel biomarkers by UHPLC-HRMS to assist the discrimination between colorectal adenoma and cancer

UHPLC-HRMS–based serum lipisdomics reveals novel biomarkers to assist in the discrimination between colorectal adenoma and cancer

Recent Progress in Mass Spectrometry-based Metabolomics for Colorectal Cancer

Contact Info

Product

Resources

About